

Date: 31st July, 2015

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results of the Company for the quarter ended on 30th June, 2015.

Further, we enclose herewith the following for the quarter ended on 30th June, 2015:

1. Consolidated Unaudited Financial Results.
2. Standalone Unaudited Financial Results.
3. Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.
4. Press Release dated 31st July, 2015.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited



Ajay Kumar Desai
Vice President-Finance &
Company Secretary

Encl.: A/a

CIN:

L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED


REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June, 2015

Rs. In Lacs

	Particulars	CONSOLIDATED			
		Quarter Ended			Year Ended
		June-15	March-15	June-14	March-15
	PART- I	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1	(a) Net Sales / Income from Operations				
	Domestic	30,336	27,530	27,840	1,17,394
	Exports	28,696	23,265	21,773	89,379
	Total	59,032	50,795	49,613	2,06,773
	Less : Excise Duty	791	612	248	1,505
	Net Sales / Income from Operations	58,241	50,183	49,365	2,05,268
	(b) Other Operating Income	93	115	63	344
	Total Income from Operations	58,334	50,298	49,428	2,05,612
2	Expenses				
	(a) Decrease/(Increase) in stock in trade and work in progress	(498)	447	(2,677)	(7,289)
	(b) Consumption of Raw Materials & Packing Materials	15,235	11,459	14,728	54,049
	(c) Purchase of traded goods	6,584	5,449	5,646	24,692
	(d) Employees' Cost	8,784	7,522	7,561	30,676
	(e) Marketing Expense	5,762	3,945	5,196	21,766
	(f) Research and Development Expense	4,795	3,049	2,953	12,162
	(g) Excise Duty	(14)	95	152	796
	(h) Other Expenditure	7,481	8,537	6,267	28,463
	Total Expenses	48,129	40,503	39,826	1,65,315
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	10,205	9,795	9,602	40,297
4	Other Income	3	185	18	230
5	Profit from Ordinary Activities before Interest, Depreciation, & Exceptional Items	10,208	9,980	9,620	40,527
6	Depreciation	1,289	1,096	1,071	4,441
7	Interest (Net)	62	36	56	178
8	Net Profit from Ordinary Activities before Tax	8,857	8,848	8,493	35,908
9	Tax Expense				
	Less : Provision for Current Tax	1,875	1,831	1,735	7,635
	Add : MAT Credit Entitlement	572	739	-	739
	Less : Provision for Deferred Tax Liability	572	739	293	739
10	Net Profit from Ordinary Activities after Tax	6,982	7,017	6,465	28,273
11	Share of Profit of Associates	6	16	2	20
12	Net Profit after Tax and share of profit of associates	6,988	7,033	6,467	28,293
13	Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770
14	Reserves excluding Revaluation Reserve	-	-	-	84,694
15	Basic & Diluted EPS (Not Annualised)	3.71	3.73	3.43	15.01
	PART- II				
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter				NIL
	Received during the quarter				NIL
	Disposed of during the quarter				NIL
	Remaining unresolved at the end of the quarter				NIL

Quarter Ended on 30th JUNE, 2015



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June, 2015


Rs. in lacs

	Particulars	STANDALONE			
		Quarter Ended			Year Ended
		June-15	March-15	June-14	March-15
		(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1	PART- I				
	(a) Net Sales / Income from Operations				
	Domestic	30,336	27,530	27,840	1,17,394
	Exports	27,849	22,361	20,525	85,681
	Total	58,185	49,891	48,365	2,03,075
	Less : Excise Duty	791	612	248	1,505
	Net Sales / Income from Operations	57,394	49,279	48,117	2,01,570
	(b) Other Operating Income	92	101	63	330
	Total Income from Operations	57,486	49,380	48,180	2,01,900
2	Expenses				
	(a) Decrease/(Increase) in stock in trade and work in progress	(498)	447	(2,677)	(7,289)
	(b) Consumption of Raw Materials & Packing Materials	15,235	11,459	14,728	54,049
	(c) Purchase of traded goods	6,584	5,495	5,646	24,663
	(d) Employees' Cost	8,487	7,245	7,322	29,657
	(e) Marketing Expense	5,604	3,633	4,954	20,318
	(f) Research and Development Expense	4,023	2,820	2,754	10,903
	(g) Excise Duty	(14)	95	152	796
	(h) Other Expenditure	7,238	8,545	6,037	28,022
	Total Expenses	46,659	39,739	38,916	1,61,119
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	10,827	9,641	9,264	40,781
4	Other Income	3	12	18	57
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	10,830	9,653	9,282	40,838
6	Depreciation	1,288	1,096	1,071	4,441
7	Interest (Net)	37	5	56	111
8	Net Profit from Ordinary Activities before Tax	9,505	8,552	8,155	36,286
9	Tax Expense				
	Less : Provision for Current Tax	1,875	1,843	1,714	7,625
	Add : MAT Credit Entitlement	572	739	-	739
	Less : Provision for Deferred Tax Liability	572	739	293	739
10	Net Profit from Ordinary Activities after Tax	7,630	6,709	6,148	28,661
11	Paid up Equity Share Capital	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve	-	-	-	79,586
13	Basic & Diluted EPS (Not Annualised)	4.05	3.56	3.26	15.20
	PART- II				
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter				NIL
	Received during the quarter				NIL
	Disposed of during the quarter				NIL
	Remaining unresolved at the end of the quarter				NIL

Quarter Ended on 30th June, 2015

Pending at the beginning of the quarter
Received during the quarter
Disposed of during the quarter
Remaining unresolved at the end of the quarter

NIL
NIL
NIL
NIL



Notes :

- 1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors.
- 2 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.

The key information on the standalone financial results are as under:


Particulars	Quarter Ended			Rs in Lacs
	Jun-15	Mar-15	Jun-14	Year Ended
	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
Net Sales / Income from Operations	57,486	49,380	48,180	2,01,900
Profit Before Tax	9,505	8,552	8,155	36,286
Profit After Tax	7,630	6,709	6,148	28,661

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.


Place : Vadodara

Date : 31st July, 2015

For Alembic Pharmaceuticals Limited



Chirayu Amin
Chairman and Managing Director



Visit us at www.alembic-india.com

F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India.
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Pharmaceuticals Limited;
Alembic Road,
Vadodara, 390 003

RE: **LIMITED REVIEW OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER ENDED 30th JUNE, 2015 PREPARED BY THE COMPANY.**

1. INTRODUCTION

We have reviewed the accompanying statement of unaudited consolidated financial results of **Alembic Pharmaceuticals Limited** for the quarter ended on 30th June, 2015 except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management, but have neither been reviewed nor been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a report on this Statement based on our review.

2. SCOPE OF REVIEW

- 2.1 We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether this Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 2.2 We report that the unaudited consolidated financial results have been prepared by the Company's management in accordance with the requirements of Accounting Standard 21 – Consolidated Financial Statements and Accounting Standard 23 - Accounting for Investments in Associates in Consolidated Financial Statements and Accounting Standard 27 – Financial Reporting of Interests in Joint Ventures, notified under section 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 on the basis of the separate unaudited



financial results of its (a) 100% Subsidiary i.e. Alembic Global Holding SA, Switzerland (standalone) (b) 6 Subsidiaries, a Joint Venture (which is yet to start any operational activities) and an Associate of Alembic Global Holding SA, Switzerland, and (c) An Associate of the Company. These unaudited standalone financial results have not been reviewed by us or any other Auditors and are as submitted to us by the Company's management.


The unaudited consolidated financial results of Company include

- (a) Company's share (i) in the consolidated Revenue of the Subsidiary of Rs. 4267.56 Lacs for the quarter ended on 30th June, 2015 (ii) in consolidated loss of the Subsidiary of Rs. 646.05 Lakhs for the quarter ended on 30th June, 2015 and (iii) in the consolidated net assets of the Subsidiary of Rs. 7284.67 Lacs as at the quarter ended on 30th June, 2015.
- (b) Company's share in the net profit (after tax) of its Associate of Rs. 3.33 Lacs for the quarter ended on 30th June, 2015.

3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 and other recognised accounting practices and policies has not disclosed the Information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W


Rajesh S. Joshi
Partner
M.No. 38526

Place: Vadodara
Date: 31st July, 2015

K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India.
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Pharmaceuticals Limited;
Alembic Road,
Vadodara 390 003.

RE: **LIMITED REVIEW OF THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2015 PREPARED BY THE COMPANY.**

1. INTRODUCTION

We have reviewed the accompanying statement of unaudited **standalone** financial results of **Alembic Pharmaceuticals Limited** for the quarter ended on **30th June, 2015** except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management, but have neither been reviewed nor been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a report on this Statement based on our review.


2. SCOPE OF REVIEW

We conducted our review in accordance with Standard on Review Engagements (**SRE**) 2410, "**Review of Interim Financial Information Performed by the Independent Auditor of the Entity**" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether this Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W


Rajesh S Joshi
Partner
M.No. 38526

Place: Vadodara
Date: 31st July, 2015

Offices also at
Chennai Kolkata Goa
Bangalore Coimbatore

For Immediate Release

Net Revenues up 19%, Net Profit up 8%

Vadodara, 31st July, 2015

Alembic Pharmaceuticals Limited reported its performance for the first quarter ending 30th June 2015. The consolidated results were taken on record by the board of directors at a meeting held in Vadodara today.

Financial Highlights

- Net Sales up 19% to Rs 590 Crore
- Net Profit up 8% to Rs 70 crore
- India Branded Formulation up 18% to Rs. 263 crore
- International Generics up 47% for the quarter to Rs. 168 Crore

Commenting on the results, Mr. Shaunak Amin, Joint Managing Director, Alembic Pharmaceuticals Limited said "We have seen exceptional growth in the topline on all the businesses, we however have also accelerated our R&D program, which led to an expense increase of 62% which has impacted our margins"

Operational Highlights

India Branded Formulations Business

- The India Branded formulations business grew by 18% to Rs 263 crores in the quarter against Rs 223 crores
- Specialty Segment grew by 22% and Acute Segment grew by 12%
- Alembic's "Tellzy" is the fastest growing Telmisartan brand, 50% as per ORG MAT May 2015, and is now the 3rd ranked brand in the Telmisartan market.

CIN:
Page: 1 of 3
L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

International Generics

- Successful Launch of Aripiprazole Generic on Day 1
- International Generics grew by 47% to Rs 168 crores in the quarter.
- During the quarter 8 ANDA approvals were received.
- 1 DMF application was filed during the quarter, taking cumulative DMF filings of the Company to 73.
- Successfully audited by the USFDA at API Karkhadi Plant

Summary of Total Revenue is as under:

(Rs in Lacs)			
Particulars	Q1 FY16	Q1 FY15	% Change
Formulation			
India Branded	26275	22328	18%
India Generics	2859	2522	13%
International Branded	836	2268	(-)63%
International Generics	16768	11381	47%
API	11683	10631	10%
Export Incentives	611	483	
Total	59032	49613	19%

The Profit break-up is as under:

(Rs in Lacs)			
Particulars	Q1 FY16	Q1 FY15	% Change
EBITDA	10205	9602	6%
Profit Before Tax	8857	8493	4%
Net Profit after Tax	6988	6467	8%

Page: 2 of 3
L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 3007630 Email: mitanshu.shah@alembic.co.in
---	---